These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 15550114

  • 1. Effect of retinoic acid in experimental diabetic nephropathy.
    Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR.
    Immunol Cell Biol; 2004 Dec; 82(6):568-76. PubMed ID: 15550114
    [Abstract] [Full Text] [Related]

  • 2. [Effect of ginsenoside Rgl on the expression of TNF-alpha and MCP-1 in rats with diabetic nephropathy].
    Zhang LN, Xie XS, Zuo C, Fan JM.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):466-71. PubMed ID: 19627007
    [Abstract] [Full Text] [Related]

  • 3. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.
    Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G.
    Diabetes; 2009 Sep; 58(9):2109-18. PubMed ID: 19587356
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
    Zheng M, Ye S, Zhai Z, Chen Y, Li X, Yang G, Fan A, Wang Y.
    J Diabetes Complications; 2009 Sep; 23(2):124-9. PubMed ID: 18413206
    [Abstract] [Full Text] [Related]

  • 5. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy.
    Li JJ, Lee SH, Kim DK, Jin R, Jung DS, Kwak SJ, Kim SH, Han SH, Lee JE, Moon SJ, Ryu DR, Yoo TH, Han DS, Kang SW.
    Am J Physiol Renal Physiol; 2009 Jul; 297(1):F200-9. PubMed ID: 19369290
    [Abstract] [Full Text] [Related]

  • 6. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
    Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM.
    Am J Physiol Renal Physiol; 2012 Mar 15; 302(6):F647-57. PubMed ID: 22169009
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
    Wang ZS, Xiong F, Xie XH, Chen D, Pan JH, Cheng L.
    BMC Nephrol; 2015 Mar 31; 16():44. PubMed ID: 25886386
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
    Wu YG, Lin H, Qi XM, Wu GZ, Qian H, Zhao M, Shen JJ, Lin ST.
    Int Immunopharmacol; 2006 Mar 31; 6(3):445-53. PubMed ID: 16428080
    [Abstract] [Full Text] [Related]

  • 14. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H, Gao T, Raup-Konsavage WM, Cooper TK, Bronson SK, Reeves WB, Awad AS.
    Kidney Int; 2017 Mar 31; 91(3):671-682. PubMed ID: 27914709
    [Abstract] [Full Text] [Related]

  • 15. Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats.
    Yu WM, Wang H, Ren XJ, Liu JP, Wang JY.
    Nephrology (Carlton); 2012 May 31; 17(4):380-9. PubMed ID: 22243699
    [Abstract] [Full Text] [Related]

  • 16. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
    Han KH, Han SY, Kim HS, Kang YS, Cha DR.
    Inflammation; 2010 Jun 31; 33(3):137-43. PubMed ID: 19921414
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of a poly-phytocompound on early stage nephropathy secondary to experimentally-induced diabetes.
    Marotta F, Harada M, Dallah ED, Yadav H, Solimene U, Di Lembo S, Minelli E, Jain S, Chui DH.
    J Biol Regul Homeost Agents; 2010 Jun 31; 24(1):41-9. PubMed ID: 20385070
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
    Zhou S, Zhao P, Li Y, Deng T, Tian L, Li H.
    Eur J Pharmacol; 2014 Oct 05; 740():9-14. PubMed ID: 25008071
    [Abstract] [Full Text] [Related]

  • 19. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1.
    Amann B, Tinzmann R, Angelkort B.
    Diabetes Care; 2003 Aug 05; 26(8):2421-5. PubMed ID: 12882873
    [Abstract] [Full Text] [Related]

  • 20. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
    Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ.
    Am J Pathol; 2017 Nov 05; 187(11):2430-2440. PubMed ID: 28837800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.